Analytical Data
-
Gene name
etb
- Application
-
Alternative Names
(Epidermolytic toxin B)
-
Species
Staphylococcus aureus
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P09332
-
Expression Region
32-277aa
-
Molecular Weight
34.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ETB (endothelin B) receptor is a crucial component in various physiological processes, including vasodilation, cell proliferation, and neural development. The ETB receptor is known for its role in mediating the effects of endothelins, a group of potent vasoconstrictors produced by the vascular endothelium. Disruption in ETB signaling has been implicated in several diseases, such as pulmonary hypertension, cardiovascular disorders, and neurological conditions. Research focusing on the recombinant expression of ETB proteins is vital for understanding their structure and function at a molecular level. By employing recombinant DNA technology, researchers can produce ETB proteins in host systems like bacteria, yeast, or mammalian cells, allowing for detailed analysis of their biochemical properties and interactions. Characterizing these proteins through studies such as binding assays, crystallization, and functional assays provides insights into receptor signaling pathways and potential therapeutic targets. Additionally, the generation of specific ETB receptor antagonists or agonists through recombinant techniques can lead to the development of novel drugs aimed at modulating ETB activity, thus paving the way for innovative treatments for related diseases. Overall, the study of recombinant ETB proteins is crucial for advancing our understanding of endothelin biology and developing therapeutic approaches for endothelin-related pathologies.
